Related Experiment Videos
[Simvastatin and extrinsic coagulation pathway in peritoneally dialyzed patients]
Insights
Simvastatin effectively lowers cholesterol and LDL in peritoneal dialysis patients. It appears to have minimal impact on endothelial function and coagulation pathways.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Context:
- Peritoneal dialysis patients often experience dyslipidemia and increased cardiovascular risk.
- Statins, like simvastatin, are known to improve lipid profiles and hemostasis in kidney disease patients.
Purpose:
- To evaluate the effects of simvastatin on platelet function, hemostasis (extrinsic coagulation pathway, tissue factor pathway inhibitor, tissue factor, and their complexes), endothelial injury marker (von Willebrand factor), and serum lipids in hyperlipidemic peritoneal dialysis patients.
Summary:
- Simvastatin significantly reduced cholesterol and LDL levels within one month, with sustained effects.
- No significant changes were observed in von Willebrand factor or key components of the extrinsic coagulation pathway.
- Truncated tissue factor pathway inhibitor decreased after one month, and total tissue factor pathway inhibitor decreased after three months of simvastatin therapy.
Impact:
- Simvastatin demonstrates efficacy as a hypolipidemic agent in peritoneal dialysis patients.
- The study suggests simvastatin has limited or no significant effect on endothelial function and the extrinsic coagulation pathway in this patient group.
Abstract:
Peritoneally dialyzed subjects (CAPD) are prone to dyslipidemia and have a high risk of cardiovascular death. Statins (hydroxy-methylglutaryloCoA reductase inhibitors) show beneficial effects on serum lipids and hemostasis in kidney diseases. The purpose of this study was to assess platelet functions, some hemostatic parameters-extrinsic coagulation pathway-total, truncated, free TFPI (tissue factor pathway inhibitor), TF (tissue factor), TFPI/Xa and TF/VIIa complexes, as well as a marker of endothelial cell injury--von Willebrand factor--vWF and serum lipids in 10 hyperlipidemic CAPD patients treated with simvastatin (Zocor, MSD, at a dose of 10 mg at bedtime) for 3 months. Cholesterol and LDL fell significantly as early as after 1 month and remained lowered during further months of the therapy. No significant changes in von Willebrand factor, free TFPI, TF, TFPI/Xa and TF/VIIa complexes were found during therapy with simvastatin. Truncated TFPI decreased significantly as early as after 1 month and total TFPI decreased after 3 months of the therapy with simvastatin. Simvastatin is an effective hypolipemic agent. It seems that simvastatin have no or only little effect on endothelial function and extrinsic coagulation pathway in peritoneally dialyzed patients.